

References - Anti-VEGF in the treatment of AMD

1. Lewis WH. Endothelium in tissue cultures. *Am J Anat* 1922; 30:39-60.
2. Ide A. G. Baker N H. Warren S L. Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. *Am J Roentgenol* 1939; 42: 891-899.
3. Michaelson IC. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. *Trans Ophthalmol Soc UK* 1948; 68: 137-180.
4. Folkman J. Tumor angiogenesis: therapeutic implications. *New England Journal of Medicine* 1971; 285: 1182-1186.
5. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science* 1983; 219: 983-5.
6. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. *Biochem Biophys Res Commun* 1989; 161: 851-8.
7. Connolly DT, Heuvelman D, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. *J Clin Invest* 1989; 84: 1470-8.
8. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. *EMBO J* 1989; 8: 3801-6.
9. Plate KH, Warnke PC. Vascular endothelial growth factor. *J Neurooncol* 1997; 35 (3): 365-72.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med* 2003; 9 (6): 669-76.
11. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. *Mol. Endocrinol* 1991; 5: 1806-1814.
12. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. *Nat Rev Mol Cell Biol* 2006; 7 (5): 359-71.
13. Sheikpranbabu S, Kalishwaralal K, Venkataraman D, Eom SH, Park J, Gurunathan S. Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells. *J Nanobiotechnology* 2009; 7: 8.
14. Allen WR, Gower S, Wilsher S. Immunohistochemical localization of vascular endothelial growth factor (VEGF) and its two receptors (Flt-1 and KDR) in the endometrium and placenta of the mare during the oestrous cycle and pregnancy. *Reprod Domest Anim* 2007; 42 (5): 516-26.
15. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. *Prog Retin Eye Res* 2003; 22 (1): 1-29.
16. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. *Am J Pathol* 2007; 171 (1): 53-67.
17. Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. *Exp Eye Res* 2007; 85 (6): 762-71. Epub 2007 Aug 24.
18. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. *Clin Sci (Lond)* 2005; 109 (3): 227-41.
19. Slomiany MG, Rosenzweig SA. Autocrine effects of IGF-I-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19. *Am J Physiol Cell Physiol* 2004; 287 (3): C746-53. Epub 2004 May 12.
20. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. *Ophthalmology* 2009; 116 (1): 73-9.

21. Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. *Exp Eye Res* 2006; 82 (5): 798-806. Epub 2005 Dec 1.
22. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med* 1994; 331 (22): 1480-7.
23. Adamis, AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, and Yeo KT. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. *Am J Ophthalmol* 1994; 118: 445-450.
24. Tsai DC, Charng MJ, Lee FL, Hsu WM, Chen SJ. Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularisation. *Ophthalmologica* 2006; 220 (4): 246-51.
25. Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. *Br J Ophthalmol* 2004; 88 (6): 809-15.
26. Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Lüke M, Bartz-Schmidt KU, Grisanti S. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. *Am J Ophthalmol* 2006; 142 (1): 95-104.
27. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. *Invest Ophthalmol Vis Sci* 1996; 37 (5): 855-68.
28. Ogata N, Matsushima M, Takada Y, et al. Expression of basic fibroblast growth factor mRNA in developing choroidal neovascularization. *Curr Eye Res* 1996; 15:1008-18.
29. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. *Invest Ophthalmol Vis Sci* 1996; 37 (9): 1929-34.
30. Rudolf M, Winkler B, Aherrahou Z, Doebring LC, P Kaczmarek, Schmidt-Erfurth U. Increased expression of vascular endothelial growth factor associated with accumulation of lipids in Bruch's membrane of LDL receptor knockout mice. *Br J Ophthalmol* 2005; 89 (12): 1627-1630.
31. Boulton ME, Cai J, Grant MB. gamma-Secretase: a multifaceted regulator of angiogenesis. *J Cell Mol Med* 2008; 12 (3): 781-95. Epub 2008 Feb 8.
32. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. *Am J Physiol Cell Physiol* 2001; 280 (6): C1358-66.
33. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. *Drugs* 2008; 68 (8): 1029-36.
34. Raig ET, Jones NB, Varker KA, Benniger K, Go MR, Biber JL, Lesinski GB, Carson WE 3rd. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. *J Interferon Cytokine Res* 2008; 28 (9): 553-61.
35. Michels S, Schmidt-Erfurth U, Rosenfeld PJ. Promising new treatments for neovascular age-related macular degeneration. *Expert Opin Investig Drugs* 2006; 15 (7): 779-93.
36. Hayek S, Scherrer M, Barthelmes D, Fleischhauer JC, Kurz-Levin MM, Menghini M, Helbig H, Sutter FK. First clinical experience with anecortave acetate (Retaane). *Klin Monbl Augenheilkd* 2007; 224 (4): 279-81.
37. Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. *BioDrugs* 2007; 21 (4): 245-57.
38. Emerson MV, Lauer AK Current and emerging therapies for the treatment of age-related macular degeneration. *Clin Ophthalmol* 2008; 2 (2): 377-88.

39. Steinbrook R. The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. *N Engl J Med* 2006; 355 (14): 1409-12.
40. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2006;355:1419-1431. Abstract
41. Brown DM, Kaiser PK, Michels M, et al, for the Anchor Study Group. Comparison of ranibizumab and verteporfin photodynamic therapy for neovascular age-related macular degeneration. *N Engl J Med*. 2006;355:1432-1444.
42. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. *Retina* 2006; 26 (8): 859-70.
43. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). *Ophthalmology* 2007; 114 (12): 2179-82.
44. Rouvas AA, Papakostas TD, Vavvas D, Vergados I, Moschos MM, Kotsolis A, Ladas ID. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatic proliferation: a prospective study. *Retina* 2009; 29 (4): 536-44.
45. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. *Ophthalmol Clin North Am* 2006; 19 (3): 361-72.
46. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J; Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. *Arch Ophthalmol* 2009; 127 (1): 13-21.
47. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med*. 2006;355:1432-44.
48. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2006;355:1419-31.
49. Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. *Ophthalmology* 2007; 114 (10): 1868-75.
50. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. *Am J Ophthalmol* 2008; 145 (2): 239-248.
51. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, Markabi S, Schmidli H, Weichselberger A. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. *Invest Ophthalmol Vis Sci* 2010; 51 (1): 405-12.
52. Bolz M, Schmidt-Erfurth U. Ranibizumab EXCITE study: Exploring the value of optical coherence tomography for the management of ranibizumab therapy in age-related macular degeneration. Presented at the 8th EURETINA Congress, Vienna, Austria 22-25 May 2008.
53. Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. *Invest Ophthalmol Vis Sci* 2009; 50 (8): 3629-35.
54. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. *Am J Ophthalmol* 2009; 148 (1): 43-58.e1.
55. Dafer RM, Schneck M, Friberg TR, Jay WM. Intravitreal ranibizumab and bevacizumab: a review of risk. *Semin Ophthalmol* 2007; 22 (3): 201-4.
56. NCT00331864. SUSTAIN: Study of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Available at <http://www.clinicaltrials.gov/ct2/show/NCT00331864> . Accessed January 18, 2010.
57. NICE Final Guidance. Ranibizumab and pegaptanib for age-related macular degeneration. At

58. Sadda S. HORIZON extension trial of ranibizumab for neovascular age-related macular degeneration: First-year safety and efficacy results. Presented at the Annual Meeting of the Retina Society, Scottsdale, Ariz., Sept 28, 2008.
59. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. *Am J Ophthalmol* 2008; 145 (5): 862-74.
60. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. *Arch Ophthalmol* 2002; 120 (3): 338 -46
61. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* 2004; 351 (27): 2805 -16
62. Sivaprasad S. Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration. *Clin Ophthalmol*. 2008 Jun; 2(2):339-46
63. Waheed NK, Miller JW. Aptamers, intramers, and vascular endothelial growth factor. *Int Ophthalmol Clin*. 2004 Summer; 44(3):11-22.
64. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results Expert Opin. Pharmacother. (2008) 9(3) 507 from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. *Ophthalmology* 2007; 114 (9): 702 -12.
65. Apte RS. Pegaptanib sodium for the treatment of age-related macular degeneration. *Expert Opin Pharmacother*. 2008 Feb; 9(3):499-508.
66. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. *Pharm Res* 2000; 17 (12): 1503 -10.
67. Eyetech Study Group. Preclinical and Phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. *Retina* 2002; 22 (2): 143 -52.
68. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularisation secondary to age-related macular degeneration: Phase II study results. *Ophthalmology* 2003; 110 (5): 979 -86
69. Ruckman J, Green LS, Beeson J, et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. *J Biol Chem* 1998; 273 (32): 20556 -67.
70. Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. *Retina*. 2005 Oct-Nov; 25(7):815-27.
71. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. *Can J Ophthalmol* 2005 ; 40 (3): 352 -68.
72. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. *Ophthalmology* 2006; 113 (9): 1508, e1501-25.
73. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. *Ophthalmology* 2006; 113 (6): 992 -1001.
74. Suner IJ. Safety of pegaptanib sodium in age-related macular degeneration (AMD): 3-year results of the VISION trial. Annual Meeting of the American Academy of Ophthalmology, Las Vegas, Nevada; 2006.
75. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular

- degeneration. *Annu Rev Med* 2007; 58: 491 -504.
76. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. *Br J Cancer* 2007; 96 (12): 1788 -95.
 77. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. *Nat Rev Cancer* 2007; 7 (6): 475 -85.
 78. Ferrara N, Hillan KJ, Nowotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. *Biochem Biophys Res Commun*. 2005; 333:328-35.
 79. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. *Cancer Res*. 1997; 57:4593-9.
 80. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. *N Engl J Med*. 2004; 350:2335-42.
 81. Yang JC, Harworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for mewztastic renal cancer. *N Engl J Med*. 2003; 349:427-34.
 82. Rosenfeld PJ, Mosfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. *Ophthalmic Surg Lasers Imaging*. 2005;36:331-5.
 83. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. *Ophthalmic Surg Lasers Imaging*. 2005;36:336-9.
 84. Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. *Ophthalmology*. 2009 Oct;116(10 Suppl):S15-23.
 85. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. *Am J Ophthalmol* 2006;142:1-9.
 86. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Retina* 2006;26:495- 511.
 87. Bressler SB. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. *Ophthalmology*. 2009 Oct;116(10 Suppl):S1-7.
 88. Hudson PJ, Souriau C. Engineered antibodies. *Nat Med* 2003;9:129 -34.
 89. Mordini J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of ¹²⁵I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. *Toxicol Pathol* 1999;27:536-44.
 90. Mordini J, Thomsen K, Licko V, et al. Intraocular pharmacokinetics and safety of a humanized monoclonal anti-body in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. *Toxicol Sci* 1999;52:101- 6.
 91. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Ophthalmology* 2006;113:363-72.
 92. Gunther JB, Altaweil MM. Bevacizumab (Avastin) for the treatment of ocular disease. *Surv Ophthalmol*. 2009 May-Jun;54(3):372-400.
 93. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. *Retina* 2007;27:439-44.
 94. Goff MJ, Johnson RN, McDonald HR, et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. *Retina* 2007; 27:432-8.
 95. Spaide RF, Laud K, Fine JFF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. *Retina*. 2006; 26:383—90

96. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. *Retina*. 2006; 26:994–8.
97. Ehrlich R, Weinberger D, Priel E, Axer-Siegel R. Outcome of bevacizumab (avastin) injection in patients with age-related macular degeneration and low visual acuity. *Retina*. 2008; 28(9):1302–7.
98. Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology. *Indian J Ophthalmol*. 2007 Nov-Dec;55(6):417-20.
99. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. for the Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). *Graefes Arch Clin Exp Ophthalmol*. 2008; 246(1):81–7.
100. Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M. Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: A preliminary multifocal-ERG and OCT study: Multifocal-ERG after use of bevacizumab in ARMD. *Doc Ophthalmol*. 2007;114:37-44.
101. Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. *Graefes Arch Clin Exp Ophthalmol*. 2007 Dec; 245(12):1837-42. Epub 2007 Mar 9.
102. Luke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, Schneider T, et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. *Br J Ophthalmol*. 2006;90:1178–82.
103. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). *Retina*. 2006;26:257–61.
104. Luthra S, Narayanan R, Marques LF, Chwa M, Kim DW, Dong J, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal and microvascular endothelial cells. *Retina*. 2006;26:512–8.
105. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA., Jr Safety of intravitreal injection of bevacizumab in rabbit eyes. *Retina*. 2006;26:882–8.
106. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Preclinical safety evaluation of Intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. *Invest Ophthalmol Vis Sci*. 2007; 48:1773–81.
107. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. *Ophthalmology*. 2005; 112(6):1035–47.
108. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. *Ophthalmology*. 2006;113(11):1–12.
109. American Society of Retina Specialists. Preferences And Trends Survey. Palm Springs, CA 2007.

[View PDF](#)